Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239(4839):487–91., , et al.
Polymerase chain reaction. J Clin Immunol 1989;9(6):437–47.
Optimization strategies for the polymerase chain reaction. Biotechniques 1989;7(7):762–9.
Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 1996;242(1):84–9., , , ,
Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing. Genome Res 2000;10(8):1249–58., ,
Pyrosequencing: history, biochemistry and future. Clin Chim Acta 2006;363(1–2):83–94., ,
Detection of DNA variation in cancer. Pharmacogenetics 1992;2(6):317–28., , ,
Capillary electrophoresis of DNA for molecular diagnostics. Electrophoresis 1997;18(10):1709–14.,
An improved method for detection of B-lymphoid clonality by polymerase chain reaction. Leukemia 1991;5(8):726–30., , ,
Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets: report of the BIOMED-2 Concerted Action BHM4-CT98–3936. Leukemia 2007;21(2):207–14., , et al.
Detection of clonality in childhood B-lineage acute lymphoblastic leukaemia by the polymerase chain reaction. Leukemia 1992;6(4):289–94., , ,
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia 2003;17(12):2257–317., , et al.
Clonal selection in acute lymphoblastic leukaemia demonstrated by polymerase chain reaction analysis of immunoglobulin heavy chain and T-cell receptor delta chain rearrangements. Leukemia 1993;7:1066–70., , ,
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106(6):2162–68., , et al.
The JAK2 V617F mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005;106(8):2920–1., , et al.
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7(4):387–97., , et al.
The myeloproliferative disorders. New Engl J Med 2006;355(23):2452–66.,
A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. Am J Clin Pathol 2007;127(6):977–81., ,
Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn 2009;11(1):49–53., , et al.
Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica 2008;93(10):1560–4., ,
Approaches to messenger RNA detection – comparison of methods. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003;147(2):131–135., ,
Chronic myelogenous leukemia, BCR-ABL1+. Am J Clin Pathol 2009;132(2):250–60.
Clinical value of PCR in diagnosis and follow-up of leukemia and lymphoma: Report of the third workshop of the molecular biology/BMT study group. Leukemia 1991;5:448–51., , et al.
Minimal residual disease in acute myeloid leukaemia. Best Pract Res Clin Haematol 2002;15(1):119–35.
A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cells with t(8;21) in peripheral blood. Eur J Haematol 2000;64(4):252–8., , et al.
Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000;95(3):815–19., , et al.
Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR. Leuk Lymphoma 1998;31(1–2):115–20.,
Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2009;144(4):517–23., , et al.
Minimal residual disease levels assessed by NPM1 mutation specific RQ-PCR provide important prognostic information in AML. Blood 2009;114(11):2220–31., , et al.
Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression. Clin Chim Acta 2008;395(1–2):120–3., , et al.
Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia. Leukemia Research 2007;31(9):1205–11., , et al.
Nucleophosmin gene mutations in acute myeloid leukemia. Arch Pathol Lab Med 2006;130(11):1687–92., ,
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93(9):3074–80., , et al.
FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000;111(1):190–5., , et al.
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001;113(4):983–8., , et al.
Point mutations in the FLT3 gene in AML. Blood 2001; 97(8): 2193A–22193.
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59–66., , et al.
Flt3 mutations and leukaemia. Br J Haematol 2003;122(4):523–38., ,
FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk Lymphoma 2003;44(1):1–7.
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008;111(3):1552–9., , et al.
Structural and functional alterations of FLT3 in acute myeloid leukemia. Clinical Cancer Research 2009;15(13):4263–9.,
Milestones and monitoring in patients with CML treated with imatinib. Hematol Am Soc Hematol Educ Program 2008;2008(1):419–26.
Monitoring of minimal residual disease in chronic myeloid leukemia. Hematol Oncol Clin N Am 2004;18(3):657–70., ,
Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy. Semin Hematol 2009;46(2 Suppl. 3):S11–15.,
Monitoring treatment results in patients with chronic myelogenous leukemia. Clin Adv Hematol Oncol 2008;6(8):577–8, 586.
Targeted therapies in myeloid leukemia. Semin Cancer Biol 2004;14(1):41–62., , ,
International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res 2008;32(3):505–6., , ,
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27(25):4204–10., , et al.
Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction. Clin Lymphoma Myeloma 2009;9(Suppl. 3):S266–71.,
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol 2008;35(1 Suppl. 1):S1–17., , et al.
The pathogenesis of acute promyelocytic leukaemia: Evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol 1999;106:591–613.
Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002;16(10):1959–73.,
Guidelines on the management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2008;113:1875–91., , et al.
GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005;106(2):447–53., , et al.
Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter “AIDA” trial. GIMEMA-AIEOP Multicenter “AIDA” Trial. Blood 1998;92(3):784–9., , et al.
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286(5439):531–7., , et al.
, , et al. The clinical utility of microarray-based gene expression profiling in the diagnosis and sub-classification of leukemia: report on 3248 cases from the international MILE study group. J Clin Oncol in press.
Applications of microarray technology to acute myelogenous leukemia. Cancer Inform 2009;7:13–28., , , ,
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. New Engl J Med 2004;350(16):1605–16., , et al.
Gene expression profiling in acute myeloid leukemia. Curr Opin Hematol 2005;12(1):76–81., ,
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome (MDS). Blood 2009;114:1063–72., , et al.
Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML?Best Pract Res Clin Haematol 2008;21(1):21–8.
Gene expression profile related to prognosis of acute myeloid leukemia. Oncol Rep 2007;18(6):1395–402., , et al.
Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. Arch Pathol Lab Med 2006;130(4):483–520.
Gene expression profiling in acute myeloid leukemia. J Clin Oncol 2005;23(26):6296–305.,
Large-scale gene expression analysis in molecular target discovery. Leukemia 2002;16(4):473–7.,
A multiple kernel support vector machine scheme for feature selection and rule extraction from gene expression data of cancer tissue. Artif Intell Med 2007;41(2):161–75., ,
Classification of multiple cancer types by multicategory support vector machines using gene expression data. Bioinformatics 2003;19(9):1132–9.,
A roadmap of clustering algorithms: finding a match for a biomedical application. Brief Bioinform 2009;10(3):297–314., , ,
Clustering approaches to identifying gene expression patterns from DNA microarray data. Mol Cells 2008;25(2):279–88.,
Reducing microarray data via nonnegative matrix factorization for visualization and clustering analysis. J Biomed Inform 2008;41(4):602–6., ,
Clustering gene expression data with kernel principal components. J Bioinform Comput Biol 2005;3(2):303–16., , ,
Multidimensional support vector machines for visualization of gene expression data. Bioinformatics 2005;21(4):439–44., , , ,
Marker identification and classification of cancer types using gene expression data and SIMCA. Methods Inf Med 2004;43(1):4–8., ,
Prognostically useful gene-expression profiles in acute myeloid leukemia. New Engl J Med 2004;350(16):1617–28., , et al.
Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia. Semin Oncol 2008;35(4):356–64.,
Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 2009;114(23):4847–58., , , ,